{
    "Case ID": "015074",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Is the '595 patent for a 70 mg weekly alendronate dosage valid, or is it obvious in light of prior art?"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Procedural_Stage": [
        "Application to prevent marketing of generic version"
    ],
    "Evidence_Assessment": [
        "Higher doses of alendronate were known to be safe and effective; Lunar News articles suggested dose adjustments for compliance"
    ],
    "Decision_Outcome": [
        "'595 patent is invalid due to obviousness"
    ],
    "Burden_of_Proof": [
        "On Merck to prove patent validity"
    ],
    "Credibility_Factor": [
        "Expert testimony and prior publications considered credible"
    ],
    "Legal_Rule": [
        "A patent is invalid if its claimed invention is obvious to a person skilled in the art based on prior knowledge and publications"
    ],
    "Standard_of_Review": [
        "Obviousness under patent law"
    ],
    "Procedural_Issue": [
        "Merck's application under NOC Regulations to block Apotex's generic entry"
    ],
    "Grounds_for_Claim": [
        "Apotex challenged the '595 patent as obvious"
    ],
    "Outcome_on_Merits": [
        "Patent found invalid; no infringement proceeding reached"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Merck's application dismissed"
    ],
    "Review_Standard": [
        "Obviousness based on prior art"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing conducted with evidence and expert testimony"
    ],
    "Key_Evidence_Considered": [
        "Prior art, Lunar News articles, expert testimony on dosing regimens"
    ],
    "Legal_Framework": [
        "Canadian patent law, particularly NOC Regulations"
    ],
    "Applicant_Challenge": [
        "Merck sought to prevent generic market entry by Apotex"
    ],
    "Court_Result": [
        "Dismissed Merck's application"
    ],
    "Legal_Rule_Source": [
        "Patent Act and case law on obviousness"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Apotex argued the patent was obvious and invalid"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert opinion, prior publications"
    ],
    "Remedy_Requested": [
        "Prevention of generic drug marketing by Apotex"
    ],
    "Outcome": [
        "Apotex entitled to proceed with marketing generic alendronate"
    ],
    "Decision_Authority": [
        "Court"
    ],
    "Remedy_Sought": [
        "Interim injunction against Apotex under NOC Regulations"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on patent validity"
    ],
    "Legal_Provision": [
        "Section 6 of the Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Authority": [
        "Federal Court (implied jurisdiction)"
    ],
    "Claimant_Status": [
        "Patent holder (Merck)"
    ],
    "Legal_Provision_Cited": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Obviousness of the patented invention"
    ],
    "Applicable_Process": [
        "NOC proceeding for patent dispute resolution"
    ],
    "Outcome_of_Review": [
        "Patent declared invalid; application dismissed"
    ],
    "Pending_Relief_or_Application": [
        "Merck's application to prevent market entry"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Obviousness test under Canadian patent law"
    ]
}